

## Amyloid Peptide

International Edition: DOI: 10.1002/anie.201508597  
German Edition: DOI: 10.1002/ange.201508597Free Superoxide is an Intermediate in the Production of  $\text{H}_2\text{O}_2$  by Copper(I)-A $\beta$  Peptide and  $\text{O}_2$ 

Karine Reybier,\* Sara Ayala, Bruno Alies, João V. Rodrigues, Susana Bustos Rodriguez, Giovanni La Penna, Fabrice Collin, Cláudio M. Gomes, Christelle Hureau, and Peter Faller\*

**Abstract:** Oxidative stress is considered as an important factor and an early event in the etiology of Alzheimer's disease (AD). Cu bound to the peptide amyloid- $\beta$  (A $\beta$ ) is found in AD brains, and Cu-A $\beta$  could contribute to this oxidative stress, as it is able to produce in vitro  $\text{H}_2\text{O}_2$  and  $\text{HO}^\bullet$  in the presence of oxygen and biological reducing agents such as ascorbate. The mechanism of Cu-A $\beta$ -catalyzed  $\text{H}_2\text{O}_2$  production is however not known, although it was proposed that  $\text{H}_2\text{O}_2$  is directly formed from  $\text{O}_2$  via a 2-electron process. Here, we implement an electrochemical setup and use the specificity of superoxide dismutase-1 (SOD1) to show, for the first time, that  $\text{H}_2\text{O}_2$  production by Cu-A $\beta$  in the presence of ascorbate occurs mainly via a free  $\text{O}_2^{\cdot-}$  intermediate. This finding radically changes the view on the catalytic mechanism of  $\text{H}_2\text{O}_2$  production by Cu-A $\beta$ , and opens the possibility that Cu-A $\beta$ -catalyzed  $\text{O}_2^{\cdot-}$  contributes to oxidative stress in AD, and hence may be of interest.

There is a large body of evidence that brains of Alzheimer disease (AD) patients are exposed to oxidative stress during the course of the disease. This is supported through high levels of oxidized proteins, lipid peroxidation, and nuclear and mitochondrial DNA oxidation.<sup>[1,2]</sup> Increased reactive oxygen species (ROS) concentrations were reported, which could be due to their overproduction or a failure in the *anti* ROS defense systems.<sup>[3,4]</sup> Although it is not clear to what extent ROS play a causal role, oxidative stress is considered as an important factor and an early event in AD.<sup>[5,6]</sup>

In amyloid plaques, a hallmark of AD, high concentrations of copper ions are found bound to the peptide amyloid- $\beta$  (A $\beta$ ), the major ingredient of the plaques.<sup>[7]</sup> The major A $\beta$  peptides are 40 (A $\beta$ 40) or 42 (A $\beta$ 42) amino acids long.

Copper ions can be a very efficient catalyst for the production of ROS<sup>[8]</sup> and in vitro and in vivo experiments suggested that a misregulation of copper is connected to AD.<sup>[7,9,10]</sup> In vitro, Cu bound to A $\beta$  (Cu-A $\beta$ ) or to the truncated N-terminal domain (A $\beta$ 16) was able to catalyze the production of  $\text{H}_2\text{O}_2$  in the presence of oxygen and biological reducing agents like ascorbate. Initial reports that A $\beta$  without metal ions could produce ROS could not be confirmed, and hence for a substantial ROS production, Cu and a reduction agent is needed.<sup>[11–15]</sup> Under the same conditions, generation of  $\text{HO}^\bullet$  catalyzed by Cu-A $\beta$  was also reported,<sup>[16–18]</sup> and found to be deleterious for the peptide itself.<sup>[19,20]</sup> Cu-A $\beta$  is less active in ROS production than Cu in a buffer, but more active than several biological relevant Cu-peptides/proteins.<sup>[17]</sup> Hence the biological relevance will depend on the so far ill-defined presence of “free” Cu and Cu-peptides/proteins near the localization of A $\beta$ , like in certain synaptic clefts. Recently, Cu-binding was also studied to N-terminal truncated and/or modified A $\beta$  peptides, forms that might be highly relevant in AD.<sup>[21,22]</sup>

In contrast to the well supported production of  $\text{H}_2\text{O}_2$  and  $\text{HO}^\bullet$ , detection of  $\text{O}_2^{\cdot-}$  by nitro blue tetrazolium (NBT) or hydroethidine failed. It was generally proposed that production of  $\text{H}_2\text{O}_2$  from  $\text{O}_2$  occurs directly via a 2-electron process without any release of  $\text{O}_2^{\cdot-}$  (Scheme 1, mechanism 2).<sup>[9,14,18,23,24]</sup>

This seems coherent, because considering the redox potentials at neutral pH the electron reduction from  $\text{O}_2$  to  $\text{H}_2\text{O}_2$  is a down-hill reaction (exergonic), in contrast to the endergonic one-electron reduction of  $\text{O}_2$  to  $\text{O}_2^{\cdot-}$ . Computational chemistry supported that Cu<sup>I</sup>-A $\beta$  can activate  $\text{O}_2$  to form  $\text{O}_2^{\cdot-}$ ,<sup>[25,26]</sup> and that no  $\text{O}_2^{\cdot-}$  is released during the  $\text{H}_2\text{O}_2$

[\*] Dr. K. Reybier, Dr. F. Collin  
University of Toulouse, UPS; UMR 152 PHARMA-DEV  
118 route de Narbonne, 31062 Toulouse cedex 9 (France)  
and  
IRD, UMR 152, 31062 Toulouse cedex 9 (France)  
E-mail: karine.reybier-vuattoux@univ-tlse3.fr  
S. Ayala, Dr. B. Alies, S. Bustos Rodriguez, Dr. F. Collin,  
Dr. C. Hureau, Prof. Dr. P. Faller<sup>[++]</sup>  
CNRS, LCC (Laboratoire de Chimie de Coordination)  
205 route de Narbonne, BP 44099, 31077 Toulouse Cedex 4 (France)  
and  
University of Toulouse, UPS, INPT  
31077 Toulouse Cedex 4 (France)  
E-mail: pfaller@unistra.fr  
Dr. J. V. Rodrigues,<sup>[+]</sup> Dr. C. M. Gomes<sup>[++]</sup>  
Instituto Tecnologia Química e Biológica, Universidade Nova de  
Lisboa, Oeiras (Portugal)


Dr. G. La Penna  
CNR – National Research Council of Italy, ICCOM – Institute for  
Chemistry of Organo-Metallic Compounds  
via Madonna del Piano 10, 50019 Sesto Fiorentino, Firenze (Italy)

[+] Present address: Harvard University, Department of Chemistry and  
Chemical Biology, Cambridge, MA (USA)

[++] Present address: Faculdade de Ciências, Biosystems and Integrative  
Sciences Institute and Department of Chemistry and Biochemistry,  
Universidade de Lisboa, Campo Grande, Lisboa (Portugal)

[+++] Present address: Institute de Chimie (UMR 7177)  
4 rue B. Pascal, 67081 Strasbourg (France)

Supporting information for this article is available on the WWW  
under <http://dx.doi.org/10.1002/anie.201508597>.




**Scheme 1.** Two potential mechanisms of  $\text{H}_2\text{O}_2$  production from  $\text{O}_2$  by Cu-A $\beta$ . In mechanism 1 the intermediate  $\text{O}_2^{\cdot-}$  is released from Cu-A $\beta$  after formation, and then reduced to  $\text{H}_2\text{O}_2$  by another Cu-A $\beta$ . In mechanism 2  $\text{O}_2$  is reduced to  $\text{H}_2\text{O}_2$  when bound to Cu-A $\beta$  without release of the potential intermediate  $\text{O}_2^{\cdot-}$ .

production ( $\text{O}_2^{\cdot-}$  was proposed as an intermediate bound to Cu-A $\beta$ ).<sup>[26]</sup> Here, we use an electrochemical setup and the specificity of superoxide dismutase-1 (SOD1) to show that the  $\text{H}_2\text{O}_2$  production of Cu-A $\beta$  proceeds mainly via free  $\text{O}_2^{\cdot-}$  as intermediate. The impact of these findings on ROS production therapeutic approaches in AD is discussed.

Cu-A $\beta$  is able to catalyze the reduction of  $\text{O}_2$  to  $\text{H}_2\text{O}_2$  by reducing agents such as ascorbate. In order to test whether  $\text{O}_2^{\cdot-}$  is generated as a released intermediate (Scheme 1), we used the classical test with cytochrome c (cyt c) to detect  $\text{O}_2^{\cdot-}$ .<sup>[27]</sup> Reaction of  $\text{O}_2^{\cdot-}$  studied with cyt c leads to the appearance of an absorption band at 550 nm due to reduction of the heme, that is, from ferricytochrome to ferrocytochrome. However, ascorbate could reduce cyt c directly and hence impede the detection of  $\text{O}_2^{\cdot-}$ . Indeed, cyt c was very rapidly reduced in the presence of ascorbate under our conditions (Figure S1 in the Supporting Information). This makes the detection of  $\text{O}_2^{\cdot-}$  produced by our catalytic system impossible (Cu-A $\beta$  + ascorbate +  $\text{O}_2$ ). To avoid ascorbate that interferes with  $\text{O}_2^{\cdot-}$  detection,  $\text{Cu}^{\text{II}}$ -A $\beta$  was reduced electrochemically at a constant potential.

Figure 1 top shows the results of the absorption changes of cyt c with Cu-A $\beta$ . Indeed, Cu-A $\beta$ 40 and Cu-A $\beta$ 16 exhibit an increase in absorption at 550 nm with time upon applying a redox potential of 0 V vs Ag/AgCl, in line with the production of  $\text{O}_2^{\cdot-}$  from  $\text{O}_2$ . As there could be the risk that oxygen is directly reduced at the electrode, the measurement was repeated in the absence of Cu-A $\beta$ . Under these conditions, the increase at 550 nm was much lower, showing only little direct electrochemical reduction of oxygen into  $\text{O}_2^{\cdot-}$ . Also in the presence of Cu only, very little  $\text{O}_2^{\cdot-}$  production was detected. Thus the much higher increase at 550 nm is in line with  $\text{O}_2^{\cdot-}$  production mediated by Cu-A $\beta$  reduction. To further confirm  $\text{O}_2^{\cdot-}$  production, the enzyme SOD1 was added to the sample with Cu-A $\beta$ . As SOD1 consumes  $\text{O}_2^{\cdot-}$  one expects a decrease in the detection of  $\text{O}_2^{\cdot-}$  by cyt c. Indeed, addition of SOD1 yields a marked decrease of the band at 550 nm (Figure 1 top right). Note that attempts to detect similar  $\text{O}_2^{\cdot-}$  production by EPR with different spin traps (DMPO, BMPO, and DEPMPO) from different suppliers were hampered by the large and variable background signal of the spin-trap recorded under reducing potential with the electrochemical setup.




**Figure 1.** Absorption spectrum of cytochrome c. The narrow band around 550 nm is assigned to the reduction of cyt c by  $\text{O}_2^{\cdot-}$ . Dashed line: time 0, solid line: after 2 min of electrolysis under different conditions: In the presence of Cu-A $\beta$ 40 (top left), Cu-A $\beta$ 16 (top middle) and Cu-A $\beta$ 16 + SOD1 (top right), in the absence of Cu-A $\beta$  (bottom left), and with Cu only (no A $\beta$ ) (bottom right). Conditions: 100  $\mu\text{M}$  A $\beta$ , 80  $\mu\text{M}$   $\text{Cu}^{2+}$ , 100  $\mu\text{M}$  cyt c, 100 mM phosphate pH 7.4; electrolysis: 0 V vs Ag/AgCl, SOD1: 600  $\text{u mL}^{-1}$ .

In order to test if  $\text{O}_2^{\cdot-}$  is produced and released during the well-established Cu-A $\beta$ -catalyzed reduction of  $\text{O}_2$  to  $\text{H}_2\text{O}_2$  by ascorbate, we measured the production of  $\text{H}_2\text{O}_2$  by using the amplex red assay (Figure 2). This assay is based on the production of the chromophore resorufin (absorbance at 571 nm) by conversion from amplex red with  $\text{H}_2\text{O}_2$  catalyzed by horseradish peroxidase. Upon addition of ascorbate to Cu-A $\beta$ , resorufin is formed (Figure 2 top, ●) indicative of the formation of  $\text{H}_2\text{O}_2$ .

In order to determine if the production of  $\text{H}_2\text{O}_2$  proceeds via the released intermediate superoxide (Scheme 1, mechanism 1) or not (mechanism 2), the SOD1 was added. Generally, if the production of  $\text{H}_2\text{O}_2$  originates directly from  $\text{O}_2$  (Scheme 1, mechanism 2), one would not expect any effect of SOD1 as no  $\text{O}_2^{\cdot-}$  is released. If  $\text{O}_2^{\cdot-}$  is a released intermediate, the SOD1 would be able to change the kinetics of the reaction.

This is because the rate limiting step is the reduction of  $\text{O}_2$  to  $\text{O}_2^{\cdot-}$  (which is thermodynamically an up-hill process). In the absence of SOD1, for each produced  $\text{H}_2\text{O}_2$  one slow ( $\text{O}_2$  to  $\text{O}_2^{\cdot-}$ ) and one faster reduction ( $\text{O}_2^{\cdot-}$  to  $\text{H}_2\text{O}_2$ ) have to occur (Scheme 2). Under conditions where SOD1 reacts with all  $\text{O}_2^{\cdot-}$  produced (saturating conditions), half of  $\text{O}_2^{\cdot-}$  reforms  $\text{O}_2$  which has to pass again the rate limiting step. In summary, under conditions where all the  $\text{O}_2^{\cdot-}$  produced reacts with SOD1, the rate limiting step has to be passed twice per average production of  $\text{H}_2\text{O}_2$  by ascorbate oxidation. Thus twice as slow reaction rate is expected under SOD1 saturation conditions (Scheme 2).

Indeed, addition of SOD1 resulted in a concentration-dependent decrease in the kinetics of  $\text{H}_2\text{O}_2$  production (measured by resorufin, Figure 2 top). SOD1 addition diminished the rate of  $\text{H}_2\text{O}_2$  production in a concentration-dependent manner (Figure 2 top), but leveled off at the half kinetically rate (Figure 2 inset). This supports that superoxide is formed and released. Then SOD1 dismutates half of this




**Figure 2.**  $\text{H}_2\text{O}_2$  formation by Cu-A $\beta$ 40. Top: Kinetics of production of resorufin measured by the absorption at 571 nm of Cu-A $\beta$ 40 with ascorbate (representative experiment). Resorufin is formed from amplex red by oxidation with  $\text{H}_2\text{O}_2$  catalyzed by horseradish peroxidase. Effect of SOD1: (●) 0, (■) 100, (▲) 500, (▼) 1000, (◄) 1500, and (►) 4000  $\mu\text{M}$ . Conditions: 100  $\mu\text{M}$  ascorbate, 5  $\mu\text{M}$   $\text{Cu}^{\text{II}}$ , 25  $\mu\text{M}$  A $\beta$ 40, 50 mM  $\text{KH}_2\text{PO}_4/\text{NaOH}$  pH 7.4. Inset: SOD1 concentration dependence of the initial kinetics of resorufin production (relative kinetics compared to no SOD1 addition). The average of three independent measurements with standard deviations is given. Bottom: SOD1 concentration dependence of the initial kinetics of ascorbate consumption by Cu-A $\beta$ 40 with ascorbate. Ascorbate consumption was measured by the absorption at 265 nm. Conditions: 100  $\mu\text{M}$  ascorbate, 5  $\mu\text{M}$   $\text{Cu}^{\text{II}}$ , 25  $\mu\text{M}$  A $\beta$ 40, 50 mM  $\text{KH}_2\text{PO}_4/\text{NaOH}$  pH 7.4.


superoxide toward  $\text{O}_2$  and half toward  $\text{H}_2\text{O}_2$  (Scheme 2), in line with the maximal inhibition of  $\text{H}_2\text{O}_2$  by half. Hence this suggests that superoxide is an intermediate and that the production of  $\text{H}_2\text{O}_2$  catalyzed by  $\text{Cu}^{\text{I}}\text{A}\beta$  occurs predominantly by two one-electron reduction steps and released  $\text{O}_2^{\cdot-}$  (Scheme 1, mechanism 1).

In parallel to the resorufin production, the consumption of ascorbate can be measured as well at 265 nm (Figure 2 bottom). Consistent with the superoxide formation, the rate of ascorbate oxidation dropped also to half, like the resorufin production after addition of SOD1. The slower kinetics of resorufin production upon addition of SOD1 has to be reflected by a slower ascorbate oxidation, because the electrons from ascorbate (via Cu-A $\beta$ ) are needed to form  $\text{H}_2\text{O}_2$ , which in turn induce the conversion of amplex red to resorufin (Scheme 2). Note that the same drop to half the rate in ascorbate consumption by adding SOD1 was also obtained

Without  
SOD



With  
SOD



**Scheme 2.** Production of  $\text{H}_2\text{O}_2$  from  $\text{O}_2$  via  $\text{O}_2^{\cdot-}$  in the absence (top) and presence of SOD1 (bottom). Without SOD1 the kinetics of ascorbate oxidation and  $\text{H}_2\text{O}_2$  production is dominated by the slower first reduction of  $\text{O}_2$  to  $\text{O}_2^{\cdot-}$ . The second reaction from  $\text{O}_2^{\cdot-}$  to  $\text{H}_2\text{O}_2$  is much faster. In the presence of saturating SOD1 (i.e. SOD1 outcompetes  $\text{Cu}^{\text{I}}\text{A}\beta$  for reacting with  $\text{O}_2^{\cdot-}$ ) ascorbate oxidation occurs only via the slow reaction of  $\text{O}_2$  to  $\text{O}_2^{\cdot-}$ . Hence, to form  $\text{H}_2\text{O}_2$  the slow reaction has to be passed twice (in contrast to only once in the absence of SOD1) and the kinetics is twice slower.

in the absence of amplex red (Figure S2), corroborating the results above.

Hydroethidine (also called dihydroethidium) or nitro blue tetrazolium (NBT) colorimetric assays were used in earlier studies to try to detect the presence of  $\text{O}_2^{\cdot-}$ . They did not detect any  $\text{O}_2^{\cdot-}$  production from  $\text{O}_2$  in the presence of Cu-A $\beta$  and ascorbate.<sup>[18]</sup> Hydroethidine or NBT react with  $\text{O}_2^{\cdot-}$  by a redox reaction. Thus we hypothesized that Cu-A $\beta$  (either in the  $\text{Cu}^{\text{I}}$  or  $\text{Cu}^{\text{II}}$  state) and/or ascorbate could interfere with the  $\text{O}_2^{\cdot-}$  detection, as we had observed in the case of cyt c (see above). Indeed, by using the xanthine/xanthine oxidase system that produces  $\text{O}_2^{\cdot-}$ , we could show that hydroethidine detects  $\text{O}_2^{\cdot-}$  production colorimetrically, but when ascorbate is added, this detection was abolished (see Figure S3). This is likely due to the much faster reaction of  $\text{O}_2^{\cdot-}$  with the ascorbyl radical ( $2.6 \times 10^8 \text{ M}^{-1} \text{ s}^{-1}$  at pH 7.8) compared to the reaction with hydroethidine ( $3 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ ).<sup>[28,29]</sup> This means that ascorbate interferes with the detection of  $\text{O}_2^{\cdot-}$  by hydroethidine. Similarly NBT and cyt c react relatively slow with  $\text{O}_2^{\cdot-}$  ( $6 \times 10^4$  and  $6 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ , respectively), and  $\text{O}_2^{\cdot-}$  could not be detected.<sup>[29]</sup> In contrast, SOD1 reacts very fast ( $\approx 1 \times 10^9 \text{ M}^{-1} \text{ s}^{-1}$ ),<sup>[29]</sup> which explains the impact of SOD1 addition on the  $\text{H}_2\text{O}_2$  production as shown above. These measurements and rates explain why the colorimetric assays with hydroethidine and NBT could not detect  $\text{O}_2^{\cdot-}$  produced by the system Cu-A $\beta$ , ascorbate and  $\text{O}_2$ .

Here we show for the first time strong evidence that Cu-A $\beta$  can catalyze the production of  $\text{O}_2^{\cdot-}$  in the presence of dioxygen and ascorbate. Moreover, the reduction of 50 % of

H<sub>2</sub>O<sub>2</sub> formation and ascorbate consumption by addition of SOD1 suggests that this is the major intermediate species on the way to H<sub>2</sub>O<sub>2</sub> production (Scheme 1, mechanism 1). This has mechanistical and biological consequences.

First, it shows that formation of H<sub>2</sub>O<sub>2</sub> occurs via two successive one-electron reductions (mechanism 1 in Scheme 1). The first step is the reaction of O<sub>2</sub> with Cu<sup>I</sup>-Aβ resulting in O<sub>2</sub><sup>•−</sup> and Cu<sup>II</sup>-Aβ. O<sub>2</sub><sup>•−</sup> is released from Cu<sup>II</sup>-Aβ and can then be reduced again by a Cu<sup>I</sup>-Aβ to form H<sub>2</sub>O<sub>2</sub>. To do that, one Cu center that cycles between the Cu<sup>I</sup> and Cu<sup>II</sup> state and hence transfer one electron at the time is sufficient. There is no need for a second electron donor, as it would be needed for the direct two-electron reduction from O<sub>2</sub> to H<sub>2</sub>O<sub>2</sub> (mechanism 2 in Scheme 1)—as it had been suggested from earlier studies.<sup>[30,31]</sup> Mechanism 1 is in line with more recent work suggesting that there is no amino acid in Aβ that can serve as an efficient and catalytic electron donor.<sup>[9]</sup> Moreover, this mechanism 1 is also in line with the fact that monomeric Cu-Aβ is sufficient to catalyze H<sub>2</sub>O<sub>2</sub> formation and a dimeric Cu center is not needed.<sup>[30,31]</sup>

Our findings do not only concern Cu-Aβ, they could have a general impact on a large variety of Cu-peptide complexes and their reactivity concerning O<sub>2</sub><sup>•−</sup>. A multitude of Cu complexes are able to catalyze the production of H<sub>2</sub>O<sub>2</sub> from O<sub>2</sub> in the presence of a reducing agent, and as shown here, detection via the classical compounds cyt c, NBT or hydroethidine may fail, despite the production of O<sub>2</sub><sup>•−</sup>, due to the concomitant presence of ascorbate/ascorbyl. This failure was overcome by the use of electrochemical reduction of Cu-Aβ. Apart from the absence of ascorbate in the medium, it is possible that other parameters favor the detection of O<sub>2</sub><sup>•−</sup>.

In a biological setting, the present work extends the potential role of Cu-Aβ as a catalyst in the context of oxidative stress. Thus, Cu-Aβ is not only able to catalyze the production of H<sub>2</sub>O<sub>2</sub> and HO<sup>•</sup>, but also O<sub>2</sub><sup>•−</sup>. The capacity to catalyze O<sub>2</sub><sup>•−</sup> can be an important parameter, not only for mechanistic insights, but also for biological consequences. The production of O<sub>2</sub><sup>•−</sup> can lead to other species in particular peroxynitrite, after reaction with NO<sup>•</sup>. Peroxynitrite is very deleterious and indeed several publications report on the role of peroxynitrite in neurodegenerative diseases.<sup>[32]</sup> Additionally, SOD upregulation as an early event in AD progression has been reported to be a compensatory effect against overproduction of O<sub>2</sub><sup>•−</sup>. Later during the progress of AD, SOD downregulation in the brain has been found. AD model mice with SOD deficiency showed increase Aβ oligomerization and memory impairment.<sup>[33]</sup> These reports underscore the implication of O<sub>2</sub><sup>•−</sup> in AD and our results suggest that Cu-Aβ should be considered as a potential source of this overproduction of O<sub>2</sub><sup>•−</sup> in AD. Thus SOD or SOD-mimicking compounds could be efficient in fighting against Cu-Aβ-catalyzed O<sub>2</sub><sup>•−</sup>, and hence inhibit the production of the very aggressive peroxynitrite.

## Acknowledgements

We thank the interregional cooperation programme “Inter-Bio” sponsored by the European Commission for support and

Sarah Cadet (LCC) for her help with the amplex red test. This work was partly supported by the Fundação para a Ciência e Tecnologia (FCT/MCTES, Portugal) through research grant PTDC/QUIBIQ/117789/2010 (to C.M.G.) and postdoctoral fellowship SFRH/BPD/34763/2007 (to J.V.R.).

**Keywords:** Alzheimer's disease · amyloid peptide · bioinorganic chemistry · copper · reactive oxygen species

**How to cite:** *Angew. Chem. Int. Ed.* **2016**, 55, 1085–1089  
*Angew. Chem.* **2016**, 128, 1097–1101

- [1] K. J. Barnham, C. L. Masters, A. I. Bush, *Nat. Rev. Drug Discovery* **2004**, 3, 205.
- [2] L. M. Sayre, G. Perry, M. A. Smith, *Chem. Res. Toxicol.* **2008**, 21, 172.
- [3] J. K. Andersen, *Nat. Med.* **2004**, 10, S18.
- [4] X. Zhu, B. Su, X. Wang, M. A. Smith, G. Perry, *Cell. Mol. Life Sci.* **2007**, 64, 2202.
- [5] F. Gu, M. J. Zhu, J. T. Shi, Y. H. Hu, Z. Zhao, *Neurosci. Lett.* **2008**, 440, 44.
- [6] A. Nunomura, G. Perry, G. Aliev, K. Hirai, A. Takeda, E. K. Balraj, P. K. Jones, H. Ghanbari, T. Wataya, S. Shimohama, S. Chiba, C. S. Atwood, R. B. Petersen, M. A. Smith, *J. Neuro-pathol. Exp. Neurol.* **2001**, 60, 759.
- [7] A. I. Bush, *Trends Neurosci.* **2003**, 26, 207.
- [8] A. Burg, D. Meyerstein, *Adv. Inorg. Chem.* **2012**, 64, 219.
- [9] C. Hureau, P. Faller, *Biochimie* **2009**, 91, 1212.
- [10] P. Faller, C. Hureau, G. La Penna, *Acc. Chem. Res.* **2014**, 47, 2252.
- [11] S. Turnbull, B. J. Tabner, O. M. El-Agnaf, L. J. Twyman, D. Allsop, *Free Radical Biol. Med.* **2001**, 30, 1154.
- [12] D. P. Smith, G. D. Ciccosto, D. J. Tew, M. T. Fodero-Tavoletti, T. Johansson, C. L. Masters, K. J. Barnham, R. Cappai, *Biochemistry* **2007**, 46, 2881.
- [13] C. Opazo, X. Huang, R. A. Cherny, R. D. Moir, A. E. Roher, A. R. White, R. Cappai, C. L. Masters, R. E. Tanzi, N. C. Inestrosa, A. I. Bush, *J. Biol. Chem.* **2002**, 277, 40302.
- [14] J. Mayes, C. Tinker-Mill, O. Kolosov, H. Zhang, B. J. Tabner, D. Allsop, *J. Biol. Chem.* **2014**, 289, 12052.
- [15] S. Noël, F. Perez, J. T. Pedersen, B. Aliès, S. Ladeira, S. Sayen, E. Guillon, E. Gras, C. Hureau, *J. Inorg. Biochem.* **2012**, 117, 322.
- [16] R. C. Nadal, S. E. Rigby, J. H. Viles, *Biochemistry* **2008**, 47, 11653.
- [17] L. Guilloreau, S. Combalbert, A. Sournia-Saquet, H. Marzaguil, P. Faller, *ChemBioChem* **2007**, 8, 1317.
- [18] X. Huang, M. P. Cuajungco, C. S. Atwood, M. A. Hartshorn, J. D. A. Tyndall, G. R. Hanson, K. C. Stokes, M. Leopold, G. Multhaup, L. E. Goldstein, R. C. Scarpa, A. J. Saunders, J. Lim, R. D. Moir, C. Glabe, E. F. Bowden, C. L. Masters, D. P. Fairlie, R. E. Tanzi, A. I. Bush, *J. Biol. Chem.* **1999**, 274, 37111.
- [19] L. E. Cassagnes, V. Herve, F. Nepveu, C. Hureau, P. Faller, F. Collin, *Angew. Chem. Int. Ed.* **2013**, 52, 11110; *Angew. Chem.* **2013**, 125, 11316.
- [20] C. S. Atwood, G. Perry, H. Zeng, Y. Kato, W. D. Jones, K.-Q. Ling, X. Huang, R. D. Moir, D. Wang, L. M. Sayre, M. A. Smith, S. G. Chen, A. I. Bush, *Biochemistry* **2004**, 43, 560.
- [21] C. Hureau, P. Dorlet, *Coord. Chem. Rev.* **2012**, 256, 2175.
- [22] M. Mital, N. E. Wezynfeld, T. Fraczyk, M. Z. Wiloch, U. E. Wawrzyniak, A. Bonna, C. Tumpach, K. J. Barnham, C. L. Haigh, W. Bal, S. C. Drew, *Angew. Chem. Int. Ed.* **2015**, 54, 10460; *Angew. Chem.* **2015**, 127, 10606.
- [23] X. Huang, C. S. Atwood, M. A. Hartshorn, G. Multhaup, L. E. Goldstein, R. C. Scarpa, M. P. Cuajungco, D. N. Gray, J. Lim, R. D. Moir, R. E. Tanzi, A. I. Bush, *Biochemistry* **1999**, 38, 7609.



- [24] S. Parthasarathy, B. Yoo, D. McElheny, W. Tay, Y. Ishii, *J. Biol. Chem.* **2014**, 289, 9998.
- [25] A. Mirats, J. Ali-Torres, L. Rodriguez-Santiago, M. Sodupe, G. La Penna, *Phys. Chem. Chem. Phys.* **2015**, 17, 27270.
- [26] N. Hewitt, A. Rauk, *J. Phys. Chem. B* **2009**, 113, 1202.
- [27] J. M. McCord, I. Fridovich, *J. Biol. Chem.* **1969**, 244, 6049.
- [28] H. T. Zhao, S. Kalivendi, H. Zhang, J. Joseph, K. Nithipatikom, J. Vasquez-Vivar, B. Kalyanaraman, *Free Radical Biol. Med.* **2003**, 34, 1359.
- [29] B. J. H. Bielski, D. E. Cabelli, R. L. Arudi, A. B. Ross, *J. Phys. Chem. Ref. Data* **1985**, 14, 1041.
- [30] S. Chassaing, F. Collin, P. Dorlet, J. Gout, C. Hureau, P. Faller, *Curr. Top. Med. Chem.* **2012**, 12, 2573.
- [31] D. G. Smith, R. Cappai, K. J. Barnham, *Biochim. Biophys. Acta Biomembr.* **2007**, 1768, 1976.
- [32] F. Torreilles, S. Salman-Tabcheh, M. Guerin, J. Torreilles, *Brain Res. Rev.* **1999**, 30, 153.
- [33] K. Murakami, N. Murata, Y. Noda, S. Tahara, T. Kaneko, N. Kinoshita, H. Hatsuta, S. Murayama, K. J. Barnham, K. Irie, T. Shirasawa, T. Shimizu, *J. Biol. Chem.* **2011**, 286, 44557.

Received: September 14, 2015

Published online: December 2, 2015